RGEN
Repligen
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: RGEN
- PEG Ratio
As of Jun 23, 2026, RGEN's PEG ratio of 0.43 reflects its valuation relative to its growth. This value reflects a P/E ratio of 137.36 measured against EPS growth of 319.0%.
RGEN PEG ratio history
Repligen's ten years historical PEG ratio averages out to 6.07. Compared to historical data, RGEN's 0.43 PEG ratio represents a decrease of 93%. RGEN reached its maximum PEG ratio of 58.47 during the Sep 2025 quarter over the past ten years. The Sep 2017 quarter had the bottom reading at 0.32, indicating the most optimal growth-adjusted valuation.
Repligen PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.65 | 188.34 | 289.1% |
| 2024 | N/A | N/A | -171.9% |
| 2023 | N/A | 280.94 | -80.9% |
| 2022 | 1.15 | 50.54 | 43.8% |
| 2021 | 1.09 | 113.67 | 104.4% |
| 2020 | 1.06 | 168.1 | 159.1% |
| 2019 | 13.31 | 210.23 | 15.8% |
| 2018 | N/A | 138.79 | -48.6% |
| 2017 | 0.44 | 49.03 | 111.4% |
| 2016 | 3.52 | 88.06 | 25% |
| 2015 | 8.42 | 101.04 | 12% |
| 2014 | N/A | 79.2 | -51% |
| 2013 | 2.45 | 26.75 | 10.9% |
| 2012 | N/A | 13.65 | N/A |
| 2011 | N/A | N/A | 100% |
Repligen PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.4 | 128.07 | 319% |
| Dec 2025 | 0.65 | 188.34 | 289.1% |
| Sep 2025 | 58.47 | 6,683.5 | 114.3% |
| Jun 2025 | N/A | N/A | -252.9% |
| Mar 2025 | N/A | N/A | -197.7% |
| Dec 2024 | N/A | N/A | -171.9% |
| Sep 2024 | N/A | N/A | -107.7% |
| Jun 2024 | N/A | 741.53 | -92.4% |
| Mar 2024 | N/A | 427.72 | -84.5% |
| Dec 2023 | N/A | 280.94 | -80.9% |
| Sep 2023 | N/A | 87.85 | -39.7% |
| Jun 2023 | N/A | 63.15 | -22.2% |
| Mar 2023 | 11.43 | 60.56 | 5.3% |
| Dec 2022 | 1.15 | 50.54 | 43.8% |
| Sep 2022 | 1.66 | 62.37 | 37.6% |
RGEN average PEG ratio chart
Measured against past performance, RGEN's PEG ratio comes in under the 5 and 10-year averages.
PEG comparison
Repligen's PEG of 0.43 is below the Healthcare sector and the industry average. In comparison with its Healthcare sector average of 0.56, Repligen's PEG is 23% lower.
RGEN EPS growth
RGEN Price vs fair value
RGEN PEG vs peers
Among its peers, RGEN has a PEG ratio below stocks GE and TMO, while higher than NBIX's.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| NBIX Neurocrine Biosciences Inc | 0.2 | $16.23B |
| RGEN Repligen Corp | 0.43 | $7.13B |
| BMY Bristol Myers Squibb Co | 0.47 | $113.4B |
| GE General Electric Co | 1.66 | $371.92B |
| TMO Thermo Fisher Scientific Inc | 3.9 | $174.42B |
| NVAX Novavax Inc | N/A | $1.48B |
| BMRN Biomarin Pharmaceutical Inc | N/A | $10.92B |
| PFE Pfizer Inc | N/A | $140.89B |
| CRL Charles River Laboratories International Inc | N/A | $8.99B |
| TECH BIO-TECHNE Corp | N/A | $8.81B |
Frequently asked questions
What is Repligen's PEG ratio?
RGEN shows a PEG ratio of 0.43, per Jun 23, 2026 data.
What is the 5-year average PEG ratio for Repligen (RGEN)?
RGEN shows a 5-year average PEG ratio of 7.1.
What is the highest PEG ratio for RGEN?
The Sep 2025 quarter marked the ten years high at 58.47 for RGEN's PEG ratio.
How does the current PEG ratio for RGEN compare to its historical average?
Currently, RGEN's PEG ratio is 93% lower than its 10-year historical average.
Why is Repligen's PEG ratio so low?
Rapid earnings expansion combined with a reasonable valuation yields RGEN a PEG ratio of 0.43.
How is RGEN's PEG ratio calculated (Repligen PEG ratio formula)?
PEG equals PE divided by EPS growth rate (YoY TTM). As of Jun 23, 2026, Repligen carries a P/E ratio of 137.36. Earnings grew at 319.0% over the TTM period ending Mar 2026. Applying the formula, this yields a price to earnings growth ratio of 0.43. PEG RATIO(0.43) = PE RATIO(137.36) / EPS GROWTH(319.0%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.